AbbVie Inc. (ABBV) Q1 2026 (USD): Adj. EPS 2.65 (exp. 2.59), Revenue 15bln (exp. 14.72bln). FY Adj. EPS view 14.08-14.28 (exp. 14.12)

AbbVie reported Q1 2026 earnings that beat expectations with an adjusted EPS of 2.65 compared to the expected 2.59 and revenue of 15 billion, surpassing the forecast of 14.72 billion.

Newsquawk StaffPublished On the live feed at 8 more headlines followed before this page went public
Newsquawk headlinesUTC

Iran has warned that continued US maritime piracy will soon be met with “practical and unprecedented military action,” high-ranking security source told Press TV

AstraZeneca (AZN LN) CEO says the government is moving in the right direction with regards to drug pricing and talks will occur between Europe and US of similar nature, via conference call

AbbVie Inc. (ABBV) Q1 2026 (USD): Adj. EPS 2.65 (exp. 2.59), Revenue 15bln (exp. 14.72bln). FY Adj. EPS view 14.08-14.28 (exp. 14.12)

US PRE-MARKET MOVERS: BE, NXPI, STX, V, GD, ADP, SBUX, BG, TMUS, MDLZ, HUM, BKNG, GEHC, HOOD

US BROKER MOVES: SPOT upgraded at Rosenblatt; BF.B downgraded at JPM

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Skyrizi revenue 4.48bln, Rinvoq estimate 2.12bln
  • Humira revenue 688mln.
  • Adj. GM 83.6%.
Context

The strong performance, reinforced by robust contributions from Skyrizi and Rinvoq, suggests resilience in AbbVie's portfolio, which could enhance confidence in the stock and its forward guidance.

Related headlines

The whole workspace, free to try.

Try it free